Biotech Compounds
PE-22-28
Research Compound

PE-22-28

PE-22-28 (Gly-Val-Ser-Trp-Gly-Leu-Arg) is a synthetic heptapeptide corresponding to residues 22-28 of the spadin sequence, making it a shortened spadin analog and the smallest fragment of that sequence characterized as retaining TREK-1 channel activity in vitro. CAS No.: 1801959-12-5. In electrophysiology and channel-binding assays it is described as a selective antagonist of the TREK-1 two-pore-domain potassium channel, with a reported in vitro IC50 on the order of 0.12 nM. Supplied as a lyophilized reference material for ion-channel pharmacology assays, cell-culture receptor studies, peptide-stability work, and HPLC or LC-MS/MS method development and purity determination. For research and laboratory use only; not for human or animal consumption.

Select Size
10mg
SKU: PE
Batch: 201607-01-PE10
$53.99
Ships today if ordered by 4PM EST
Est. Arrival: 09/16/2026
Volume Discounts
Qty: 1 - 4$53.99 each
Qty: 5 - 9$48.59 each(save $5.40)
Qty: 10+$43.19 each(save $10.80)
Quantity:
1
For Research Use Only. This product is intended for laboratory and scientific research purposes only. It is not a drug or dietary supplement and is not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
99%+ Purity
COA Included
Fast Shipping
USA Based
Categories:
NeurotransmitterInhibitory
Tags:
PE-22-28heptapeptideTREK-1 antagonistTREK-1 inhibitorpotassium channel inhibitortwo-pore potassium channelspadin analogsortilin-derivedPSD-95ion channel pharmacologyreceptor binding assayreference standardresearch peptide

Product Details

PE-22-28 is a seven-amino-acid synthetic peptide (Gly-Val-Ser-Trp-Gly-Leu-Arg) derived from spadin, a peptide cleaved from the propeptide region of sortilin. The sequence corresponds to the 22nd through 28th residues of spadin — the origin of its name — and was identified through screening of spadin degradation products as the minimal sequence characterized as retaining TREK-1 channel inhibitory activity in vitro. CAS No.: 1801959-12-5.


TREK-1 is a TWIK-related two-pore-domain potassium channel and a well-studied target in ion-channel pharmacology. In patch-clamp electrophysiology and channel-binding assays, PE-22-28 is characterized as a selective antagonist of this channel, with a reported in vitro IC50 on the order of 0.12 nM compared with roughly 40-60 nM for spadin measured under comparable conditions. Its reported stability in buffered laboratory matrices is likewise longer than that of spadin — on the order of 23 hours versus approximately 7 hours — a property relevant to the design of extended-timepoint assay protocols.


In cell-culture research the peptide is employed as a tool compound for probing two-pore-domain potassium channel pharmacology and for tracking expression of the postsynaptic density marker PSD-95 in cultured neuronal preparations. Because it is a short, well-defined single-sequence heptapeptide, it also serves as a convenient reference standard in reversed-phase HPLC and LC-MS/MS work, including retention-time matching, identity confirmation, purity determination, and peptide degradation and stability studies.


Disclaimer: PE-22-28 is supplied strictly for research and laboratory use only. This product is not a drug, dietary supplement, or medical device. It is not intended for human or animal consumption, and not for therapeutic, diagnostic, or clinical application. It has not been evaluated by the FDA, and no statement here should be read as a claim to diagnose, treat, cure, or prevent any condition. All handling should be performed by qualified researchers in accordance with applicable laboratory safety protocols and institutional guidelines.

Frequently Asked Questions About PE-22-28

Answers summarize published research and are provided for laboratory research purposes only.

PE-22-28 is a synthetic heptapeptide with the sequence Gly-Val-Ser-Trp-Gly-Leu-Arg. It corresponds to residues 22 through 28 of spadin, a peptide released from the propeptide region of sortilin, and it was identified as the shortest spadin fragment that retains activity in vitro. Research studies have examined PE-22-28 as a selective antagonist of the TREK-1 potassium channel and as a reference standard in analytical peptide work.
In patch clamp electrophysiology and channel binding assays, PE-22-28 has been characterized as a selective antagonist of TREK-1, a two pore domain potassium channel. Researchers have reported an in vitro IC50 on the order of 0.12 nM, which is considerably more potent than spadin measured under comparable conditions. Published research suggests that blocking TREK-1 with PE-22-28 alters neuronal excitability, since TREK-1 helps set the resting potassium leak current in neurons.
Ion channel pharmacology is the main research area for PE-22-28. TREK-1 is a mechanosensitive, lipid sensitive potassium channel that researchers study as a target for understanding neuronal excitability. In cell culture, PE-22-28 has been used as a tool compound to block TREK-1 and observe the downstream effects. Research studies have reported that spadin derived peptides such as PE-22-28 spare related channels at the concentrations that block TREK-1, which supports their selectivity.
A second research area for PE-22-28 is neuroplasticity. In cultured neuronal preparations, researchers have used PE-22-28 to track expression of PSD-95, a postsynaptic density marker that indicates synapse formation. Published research on spadin and its shortened analogs reported increased PSD-95 expression and neurogenesis markers in rodent studies after TREK-1 blockade. PE-22-28 is also used in rodent behavioral models that study the consequences of TREK-1 inhibition.
PE-22-28 research is preclinical. The compound has been characterized in patch clamp electrophysiology, channel binding assays, cell culture, and rodent studies. There are no clinical trials of PE-22-28, and it is not an approved drug anywhere. It is best described as an investigational tool compound for ion channel pharmacology, and its stability data make it useful for extended timepoint assay design in laboratory settings.
PE-22-28 and Selank are both short neuroactive research peptides, but they act through unrelated mechanisms. PE-22-28 is a seven amino acid spadin fragment that research has characterized as a selective TREK-1 potassium channel antagonist. Selank is a seven amino acid analog of the tuftsin fragment that research studies have linked to GABA and serotonin signaling and to immune modulation. Both are sold by Biotech Compounds as separate lyophilized research materials.
PE-22-28 is supplied as a lyophilized powder. For research preparation it is dissolved in sterile water or Bacteriostatic Water, added slowly down the wall of the vial, and the vial is swirled gently until clear rather than shaken. Because PE-22-28 is often used in electrophysiology, researchers frequently prepare a concentrated stock and dilute it into the assay buffer on the day of the experiment. Bacteriostatic Water is available from Biotech Compounds.
Lyophilized PE-22-28 should be stored at minus 20 C, dry, sealed, and protected from light. After reconstitution, PE-22-28 should be kept at 2 to 8 C and protected from light, or frozen in single use aliquots to avoid repeated freeze thaw cycles. Research reports describe PE-22-28 as more stable than spadin in buffered laboratory matrices, on the order of 23 hours versus roughly 7 hours, which is why it is favored for longer assay protocols.
Yes. PE-22-28 from Biotech Compounds is supplied at 99 percent or greater purity, and each lot is third-party tested to confirm identity and purity. A Certificate of Analysis for PE-22-28 is available on the product page. Researchers can match the lot number on the vial to the certificate before starting an assay.
PE-22-28 has a molecular formula of C35H55N11O9 and a molecular weight of 773.89 g/mol. Its CAS number is 1801959-12-5. It is a linear seven amino acid peptide with the sequence Gly-Val-Ser-Trp-Gly-Leu-Arg. These values appear in the specifications on the PE-22-28 product page and on the Certificate of Analysis.
PE-22-28 is a short, single sequence heptapeptide with a well defined mass, which makes it convenient as a reference standard in reversed phase HPLC and LC-MS/MS work. Laboratories use PE-22-28 for retention time matching, identity confirmation, purity determination, and peptide degradation studies. Its tryptophan residue gives it useful ultraviolet absorbance for detection, and its documented stability profile supports its use in method development.
No. PE-22-28 is not an approved drug and is not a dietary supplement. Biotech Compounds sells PE-22-28 strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 years of age or older. PE-22-28 is not for human or animal consumption and is not intended for any therapeutic, diagnostic, or clinical application.
You May Also Like

Related Products

Adamax

Adamax

$85.99 / from
Aviptadil

Aviptadil

$215.99 / from
CJC-1295 (no DAC)

CJC-1295 (no DAC)

$49.99 / from
CJC-1295 W/ DAC

CJC-1295 W/ DAC

$37.99 / from